Top news for allergists from European Academy of Dermatology and Venereology Congress

For allergists interested in dermatology-focused findings from the European Academy of Dermatology and Venereology Congress but who could not attend the meeting this year in Milan, Healio presents this list of seven studies that may be relevant to your practice.

Remibrutinib safety profile continues with long-term use for chronic spontaneous urticaria

Long-term use of remibrutinib (LOU064, Novartis), an oral Bruton tyrosine kinase inhibitor, appeared safe and well tolerated for patients with chronic spontaneous urticaria, according to data from a phase 2b trial and its long-term open-label extension study. Read more.

Age of atopic dermatitis onset defines endotype of disease

Adult-onset dermatitis has distinct TH1 activation compared with adults who have childhood-onset atopic dermatitis, showing two separate endotypes defined by age of onset, according to results of a study that analyzed lesional and non-lesional skin biopsies and blood samples. Read more.

Lower disease severity associated with better quality of life in dermatitis

Patients with atopic dermatitis who displayed lower disease severity and better quality of life also had lower clinical burdens and work impairment, according to an analysis of data from the cross-sectional, 28-country MEASURE-AD study. Read more.

Less frequent lebrikizumab dosing yields similar efficacy in atopic dermatitis

Maintenance dosing of lebrikizumab (Almirall, Lilly) every 4 weeks showed similar efficacy as dosing every 2 weeks in patients with atopic dermatitis, according to new, detailed results from the ADvocate 1 and ADvocate 2 phase 3 clinical trials. Read more.

Head, neck dermatitis improved with rocatinlimab

Emma Guttman-Yassky

Patients with atopic dermatitis of the head and neck who did not have success with topical therapy experienced greater improvement with rocatinlimab (AMG 451/KHK4083; Amgen, Kyowa Kirin) treatment, according to study results presented by Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a Healio Allergy/Asthma Peer Perspective Board Member. Read more.

Pfizer’s phosphodiesterase 4 inhibitor efficacious in atopic dermatitis, psoriasis

A basket study of PF-07038124 — an oxaborole-based phosphodiesterase 4, or PDE4, inhibitor from Pfizer — modulated production of multiple cytokines and demonstrated efficacy superior to that of placebo in mild to moderate plaque psoriasis or atopic dermatitis. Read more.

Remibrutinib reduces need for rescue medication in chronic spontaneous urticaria

Remibrutinib reduced the need for second-generation H1 antihistamines as a rescue medication in patients with chronic spontaneous urticaria across all doses in a 12-week multicenter, randomized, double-blind, placebo-controlled, phase 2b study. Read more.